Ipsen SA

Late-breaking elafibranor primary sclerosing cholangitis (PSC) data demonstrates favorable safety profile and significant efficacy in second potential rare liver disease indication

24 Apr 2025 02:14:23 By Nasdaq GlobeNewswire

Ipsen delivers strong sales in the first quarter 2025 and confirms its full-year guidance

16 Apr 2025 00:57:00 By Nasdaq GlobeNewswire

Ipsen - March 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital

14 Apr 2025 12:00:00 By Nasdaq GlobeNewswire

Ipsen publishes its 2024 Universal Registration Document

08 Apr 2025 12:00:00 By Nasdaq GlobeNewswire

Ipsen announces issuance of €500 million inaugural Rated Public Bond

19 Mar 2025 02:00:00 By Nasdaq GlobeNewswire

Ipsen appoints Olivia Brown as Executive Vice-President, Global Head of Neurotoxins

12 Mar 2025 02:28:00 By Nasdaq GlobeNewswire

Ipsen - February 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital

06 Mar 2025 12:00:00 By Nasdaq GlobeNewswire

Ipsen S.A. publishes its 2024 consolidated financial statements

21 Feb 2025 09:42:27 By Nasdaq GlobeNewswire

Ipsen delivers solid results in 2024, driven by strong performance across all therapeutic areas, and provides guidance for 2025

13 Feb 2025 00:57:00 By Nasdaq GlobeNewswire

Ipsen - January 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital

06 Feb 2025 12:00:00 By Nasdaq GlobeNewswire

Ipsen - December 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital

07 Jan 2025 12:00:00 By Nasdaq GlobeNewswire

Ipsen - Half year statement - 2024 12 31

07 Jan 2025 12:00:00 By Nasdaq GlobeNewswire

Ipsen - November 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital

09 Dec 2024 12:00:00 By Nasdaq GlobeNewswire

Ipsen and Biomunex announce exclusive global licensing agreement for first-in-class MAIT cell engager in immuno-oncology

03 Dec 2024 01:00:00 By Nasdaq GlobeNewswire

Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus

15 Nov 2024 11:00:00 By Nasdaq GlobeNewswire

Ipsen - October 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital

07 Nov 2024 12:00:00 By Nasdaq GlobeNewswire

Ipsen delivers strong sales momentum in the first nine months of 2024 and increases its full-year guidance

23 Oct 2024 01:00:00 By Nasdaq GlobeNewswire

Ipsen receives its second Shingo Prize for operational excellence

14 Oct 2024 12:00:00 By Nasdaq GlobeNewswire

Ipsen - September 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital

09 Oct 2024 12:00:00 By Nasdaq GlobeNewswire

Ipsen’s Kayfanda® (odevixibat) approved in European Union for cholestatic pruritus in Alagille Syndrome, a rare liver disease

23 Sep 2024 07:13:10 By Nasdaq GlobeNewswire